JP2024150466A5 - - Google Patents

Download PDF

Info

Publication number
JP2024150466A5
JP2024150466A5 JP2024103249A JP2024103249A JP2024150466A5 JP 2024150466 A5 JP2024150466 A5 JP 2024150466A5 JP 2024103249 A JP2024103249 A JP 2024103249A JP 2024103249 A JP2024103249 A JP 2024103249A JP 2024150466 A5 JP2024150466 A5 JP 2024150466A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024103249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024150466A (ja
JP7789850B2 (ja
Filing date
Publication date
Priority claimed from JP2022557633A external-priority patent/JP7592743B2/ja
Application filed filed Critical
Publication of JP2024150466A publication Critical patent/JP2024150466A/ja
Publication of JP2024150466A5 publication Critical patent/JP2024150466A5/ja
Priority to JP2025244399A priority Critical patent/JP2026048795A/ja
Application granted granted Critical
Publication of JP7789850B2 publication Critical patent/JP7789850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024103249A 2020-05-18 2024-06-26 Lnp023の結晶形態 Active JP7789850B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025244399A JP2026048795A (ja) 2020-05-18 2025-12-10 Lnp023の結晶形態

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063026637P 2020-05-18 2020-05-18
US63/026,637 2020-05-18
US202063052699P 2020-07-16 2020-07-16
US63/052,699 2020-07-16
JP2022557633A JP7592743B2 (ja) 2020-05-18 2021-05-17 Lnp023の結晶形態
PCT/IB2021/054225 WO2021234544A1 (en) 2020-05-18 2021-05-17 Crystalline form of lnp023

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022557633A Division JP7592743B2 (ja) 2020-05-18 2021-05-17 Lnp023の結晶形態

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025244399A Division JP2026048795A (ja) 2020-05-18 2025-12-10 Lnp023の結晶形態

Publications (3)

Publication Number Publication Date
JP2024150466A JP2024150466A (ja) 2024-10-23
JP2024150466A5 true JP2024150466A5 (https=) 2025-04-07
JP7789850B2 JP7789850B2 (ja) 2025-12-22

Family

ID=76076387

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022557633A Active JP7592743B2 (ja) 2020-05-18 2021-05-17 Lnp023の結晶形態
JP2024103249A Active JP7789850B2 (ja) 2020-05-18 2024-06-26 Lnp023の結晶形態
JP2025244399A Pending JP2026048795A (ja) 2020-05-18 2025-12-10 Lnp023の結晶形態

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022557633A Active JP7592743B2 (ja) 2020-05-18 2021-05-17 Lnp023の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025244399A Pending JP2026048795A (ja) 2020-05-18 2025-12-10 Lnp023の結晶形態

Country Status (10)

Country Link
US (3) US11603363B2 (https=)
EP (1) EP4153580A1 (https=)
JP (3) JP7592743B2 (https=)
KR (2) KR20230009478A (https=)
CN (4) CN120208923A (https=)
AU (2) AU2021276912B2 (https=)
CA (1) CA3180829A1 (https=)
IL (1) IL297975A (https=)
TW (2) TWI858258B (https=)
WO (1) WO2021234544A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66635B1 (sr) 2017-08-31 2025-04-30 Novartis Ag Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije
CN120208923A (zh) * 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
AU2021414253B2 (en) * 2020-12-30 2024-05-16 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Series of piperidine-substituted benzoic acid compounds, and use thereof
MX2023013148A (es) * 2021-05-07 2023-11-28 Novartis Ag Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
JP2024522769A (ja) 2021-06-18 2024-06-21 ノバルティス アーゲー 自己免疫性血液学的疾患を治療する方法
IL314494A (en) 2022-03-04 2024-09-01 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
JP7849520B2 (ja) * 2022-06-30 2026-04-21 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 含窒素架橋複素環誘導体の薬学的に許容される塩、結晶形及びその調製方法
WO2024176169A1 (en) 2023-02-23 2024-08-29 Novartis Ag Methods of using factor b inhibitors
TW202508580A (zh) 2023-08-25 2025-03-01 瑞士商諾華公司 使用因子b抑制劑之方法
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
TW202533829A (zh) 2024-02-16 2025-09-01 瑞士商諾華公司 用於治療anca相關性血管炎的因子b抑制劑
WO2026003809A1 (en) * 2024-06-29 2026-01-02 Assia Chemical Industries Ltd. Solid state forms of iptacopan hydrochloride

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
KR20180091097A (ko) 2015-12-23 2018-08-14 그리노파티온 바이오테크 게엠베하 보체 활성화를 억제하기 위한 폴리펩티드
RS66635B1 (sr) 2017-08-31 2025-04-30 Novartis Ag Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije
CN120208923A (zh) * 2020-05-18 2025-06-27 诺华股份有限公司 Lnp023的结晶形式

Similar Documents

Publication Publication Date Title
JP2024036694A5 (https=)
JP2024032941A5 (https=)
JP2025041734A5 (https=)
JP2025069142A5 (https=)
JP2024150466A5 (https=)
JP2023526975A5 (https=)
JP2022122972A5 (https=)
JP2024116190A5 (https=)
JP2024114921A5 (https=)
JP2022185040A5 (https=)
JP2024161376A5 (https=)
JP2025176106A5 (https=)
JP2023182571A5 (https=)
JP2024026077A5 (https=)
JP2023133317A5 (https=)
JP2023116477A5 (https=)
JP2025098156A5 (https=)
JP2020079331A5 (https=)
JP2025148617A5 (https=)
JP2022064180A5 (https=)
JP2022518056A5 (https=)
JP2025094038A5 (https=)
JP2025090801A5 (https=)
JP2024149687A5 (https=)
JP2025003964A5 (https=)